Based on the limited data from clinical trials available so far, whether in first-line or later-line treatment, the clinical benefit of the BRAF mutation subgroup in the MSI-H/dMMR metastatic colorectal cancer population did not significantly vary from that of non-BRAF mutation population. This evidence concerns the gene BRAF and metastatic colorectal cancer.